Neurizon Therapeutics Ltd
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neur… Read more
Market Cap & Net Worth: Neurizon Therapeutics Ltd (NUZ)
Neurizon Therapeutics Ltd (AU:NUZ) has a market capitalization of $34.11 Million (AU$55.09 Million) as of March 19, 2026. Listed on the AU stock exchange, this Australia-based company holds position #25937 globally and #580 in its home market, demonstrating a -2.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neurizon Therapeutics Ltd's stock price AU$0.08 by its total outstanding shares 688628681 (688.63 Million).
Neurizon Therapeutics Ltd Market Cap History: 2024 to 2026
Neurizon Therapeutics Ltd's market capitalization history from 2024 to 2026. Data shows growth from $72.49 Million to $34.11 Million (0.00% CAGR).
Neurizon Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neurizon Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NUZ by Market Capitalization
Companies near Neurizon Therapeutics Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Neurizon Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Neurizon Therapeutics Ltd Historical Marketcap From 2024 to 2026
Between 2024 and today, Neurizon Therapeutics Ltd's market cap moved from $72.49 Million to $ 34.11 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$34.11 Million | -5.88% |
| 2025 | AU$36.24 Million | -50.00% |
| 2024 | AU$72.49 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Neurizon Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $34.11 Million USD |
| MoneyControl | $34.11 Million USD |
| MarketWatch | $34.11 Million USD |
| marketcap.company | $34.11 Million USD |
| Reuters | $34.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.